96 related articles for article (PubMed ID: 31028607)
1. Shared-patient physician networks and their impact on the uptake of genomic testing in breast cancer.
Rotter J; Wilson L; Greiner MA; Pollack CE; Dinan M
Breast Cancer Res Treat; 2019 Jul; 176(2):445-451. PubMed ID: 31028607
[TBL] [Abstract][Full Text] [Related]
2. Surgeon and medical oncologist peer network effects on the uptake of the 21-gene breast cancer recurrence score assay.
Zipkin R; Schaefer A; Chamberlin M; Onega T; O'Malley AJ; Moen EL
Cancer Med; 2021 Feb; 10(4):1253-1263. PubMed ID: 33455068
[TBL] [Abstract][Full Text] [Related]
3. Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010-2016.
Schwedhelm TM; Rees JR; Onega T; Zipkin RJ; Schaefer A; Celaya MO; Moen EL
BMC Cancer; 2020 Sep; 20(1):847. PubMed ID: 32883270
[TBL] [Abstract][Full Text] [Related]
4. Quantitative nuclear histomorphometry predicts oncotype DX risk categories for early stage ER+ breast cancer.
Whitney J; Corredor G; Janowczyk A; Ganesan S; Doyle S; Tomaszewski J; Feldman M; Gilmore H; Madabhushi A
BMC Cancer; 2018 May; 18(1):610. PubMed ID: 29848291
[TBL] [Abstract][Full Text] [Related]
5. ONCOLOGISTS' BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY.
Roberts MC; Bryson A; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes K; Wheeler SB
Int J Technol Assess Health Care; 2016 Jan; 32(5):355-361. PubMed ID: 27958190
[TBL] [Abstract][Full Text] [Related]
6. Low utility of Oncotype DX® in the clinic.
Ricks-Santi LJ; McDonald JT
Cancer Med; 2017 Mar; 6(3):501-507. PubMed ID: 28145091
[TBL] [Abstract][Full Text] [Related]
7. Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study.
Davis BA; Aminawung JA; Abu-Khalaf MM; Evans SB; Su K; Mehta R; Wang SY; Gross CP
J Natl Compr Canc Netw; 2017 Mar; 15(3):346-354. PubMed ID: 28275035
[No Abstract] [Full Text] [Related]
8. Oncotype DX Test Receipt among Latina/Hispanic Women with Early Invasive Breast Cancer in New Jersey: A Registry-Based Study.
Acuna N; Plascak JJ; Tsui J; Stroup AM; Llanos AAM
Int J Environ Res Public Health; 2021 May; 18(10):. PubMed ID: 34065945
[TBL] [Abstract][Full Text] [Related]
9. Association between physician characteristics and the use of 21-gene recurrence score genomic testing among Medicare beneficiaries with early-stage breast cancer, 2008-2011.
Wilson LE; Pollack CE; Greiner MA; Dinan MA
Breast Cancer Res Treat; 2018 Jul; 170(2):361-371. PubMed ID: 29536319
[TBL] [Abstract][Full Text] [Related]
10. How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients.
Zhu X; Dent S; Paquet L; Zhang T; Tesolin D; Graham N; Aseyev O; Song X
Curr Oncol; 2021 Feb; 28(1):800-812. PubMed ID: 33557029
[TBL] [Abstract][Full Text] [Related]
11. Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset.
Harowicz MR; Robinson TJ; Dinan MA; Saha A; Marks JR; Marcom PK; Mazurowski MA
Breast Cancer Res Treat; 2017 Feb; 162(1):1-10. PubMed ID: 28064383
[TBL] [Abstract][Full Text] [Related]
12. Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria.
Natsuhara KH; Losk K; King TA; Lin NU; Camuso K; Golshan M; Pochebit S; Brock JE; Bunnell CA; Freedman RA
Oncologist; 2019 May; 24(5):595-602. PubMed ID: 30076279
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Radiation Oncologists on the Early Adoption of Hypofractionated Radiation Therapy for Early-Stage Breast Cancer.
Boero IJ; Gillespie EF; Hou J; Paravati AJ; Kim E; Einck JP; Yashar C; Mell LK; Murphy JD
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):571-580. PubMed ID: 28126306
[TBL] [Abstract][Full Text] [Related]
14. Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.
Dinan MA; Mi X; Reed SD; Lyman GH; Curtis LH
JAMA Oncol; 2015 Nov; 1(8):1098-109. PubMed ID: 26313372
[TBL] [Abstract][Full Text] [Related]
15. Uptake of BRCA 1/2 and oncotype DX testing by medical and surgical oncologists.
Murciano-Goroff YR; McCarthy AM; Bristol MN; Groeneveld P; Domchek SM; Motanya UN; Armstrong K
Breast Cancer Res Treat; 2018 Aug; 171(1):173-180. PubMed ID: 29737473
[TBL] [Abstract][Full Text] [Related]
16. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ
Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662
[TBL] [Abstract][Full Text] [Related]
17. Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base.
Ibraheem A; Olopade OI; Huo D
Cancer; 2020 Sep; 126(17):4013-4022. PubMed ID: 32521056
[TBL] [Abstract][Full Text] [Related]
18. A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor‒Positive, Human Epidermal Growth Factor 2 (HER2)‒Negative Breast Cancer.
Lee SB; Kim J; Sohn G; Kim J; Chung IY; Kim HJ; Ko BS; Son BH; Ahn SH; Lee JW; Jung KH
Cancer Res Treat; 2019 Jul; 51(3):1073-1085. PubMed ID: 30384581
[TBL] [Abstract][Full Text] [Related]
19. Physician peer group characteristics and timeliness of breast cancer surgery.
Bachand J; Soulos PR; Herrin J; Pollack CE; Xu X; Ma X; Gross CP
Breast Cancer Res Treat; 2018 Aug; 170(3):657-665. PubMed ID: 29693229
[TBL] [Abstract][Full Text] [Related]
20. The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort.
Ademuyiwa FO; Miller A; O'Connor T; Edge SB; Thorat MA; Sledge GW; Levine E; Badve S
Breast Cancer Res Treat; 2011 Apr; 126(3):797-802. PubMed ID: 21197567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]